Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to -$3.3 million.

  • Lisata Therapeutics' Cash from Operations fell 3272.44% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.2 million, marking a year-over-year increase of 883.21%. This contributed to the annual value of -$19.4 million for FY2024, which is 337.46% up from last year.
  • According to the latest figures from Q3 2025, Lisata Therapeutics' Cash from Operations is -$3.3 million, which was down 3272.44% from -$4.0 million recorded in Q2 2025.
  • Lisata Therapeutics' Cash from Operations' 5-year high stood at -$2.5 million during Q3 2024, with a 5-year trough of -$8.2 million in Q1 2023.
  • In the last 3 years, Lisata Therapeutics' Cash from Operations had a median value of -$4.2 million in 2023 and averaged -$4.7 million.
  • In the last 5 years, Lisata Therapeutics' Cash from Operations skyrocketed by 2972.37% in 2024 and then plummeted by 3272.44% in 2025.
  • Over the past 3 years, Lisata Therapeutics' Cash from Operations (Quarter) stood at -$4.1 million in 2023, then decreased by 11.28% to -$4.5 million in 2024, then grew by 26.19% to -$3.3 million in 2025.
  • Its Cash from Operations stands at -$3.3 million for Q3 2025, versus -$4.0 million for Q2 2025 and -$5.4 million for Q1 2025.